Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YKYY032
- Development stage
- Phase 2
- Lead developer
- Yuekang Pharmaceutical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
YKYY032 is an investigational GalNAc-conjugated small interfering RNA (siRNA) therapeutic developed by Beijing Yuekang Kechuang Pharmaceutical Technology and Hangzhou Tianlong Pharmaceutical for the treatment of hyperlipoproteinemia (a). It utilizes a proprietary delivery platform to target the mRNA of the *LPA* gene in hepatocytes, leading to the degradation of the transcript and a subsequent reduction in the production of Apolipoprotein(a) [Apo(a)]. Since Apo(a) is a critical component of Lipoprotein(a) [Lp(a)], its suppression results in significantly lowered circulating Lp(a) levels. High Lp(a) is a genetically determined, independent risk factor for cardiovascular diseases, including myocardial infarction and stroke, for which there are currently limited targeted pharmacological treatments. YKYY032 is currently being evaluated in early-stage clinical trials to assess its safety, tolerability, and pharmacodynamic effects on Lp(a) reduction.
Beyond the preview
Go deeper on YKYY032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YKYY032.